Actively Recruiting
Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy for First-line Treatment of Unresectable or Metastatic Left-sided Colorectal Cancer
Led by Genmab · Updated on 2026-11-03
960
Participants Needed
12
Research Sites
113 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of petosemtamab combined with chemotherapy compared to cetuximab combined with chemotherapy in treating left-sided colorectal cancer that cannot be removed by surgery or has spread to other parts of the body. This Phase 3, randomized, open-label global trial involves participants with RAS and BRAF wild-type tumors, aiming to assess treatment safety and efficacy as a first-line therapy. Participants will receive either petosemtamab plus one of two chemotherapy options mFOLFOX6 or FOLFIRI or cetuximab plus the same chemotherapy choices. Treatments are administered via intravenous infusions. The study treatment duration varies per participant, continuing as long as the cancer remains stable or improves without serious issues. Treatment cycles last 4 weeks, with participants attending two clinic visits per cycle for monitoring. During the study, participants will undergo blood tests and imaging to check treatment safety and effectiveness. Researchers will measure outcomes such as progression-free survival and objective response rate up to about 35 months, and additional measures like overall survival and quality of life up to about 62 months. The total time involved in the study, including screening, treatment, and follow-up, depends on each participants individual course.
CONDITIONS
Brief Title
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
Research Team
G
Genmab Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here